Underlying mechanisms contributing to cardiovascular and renal protection are at least partially different between GLP-1RAs (mainly anti-atherogenic and vascular effects) and SGLT2is (mainly systemic and intrarenal hemodynamic changes)
Evidence was reported according to the neuropsychiatric condition under investigation: cognitive disorders (dementia, Parkinsons disease), substance-use disorders, psychotic disorders, mood and anxiety disorders, and eating disorderseach subdivided into pre-clinical and mechanistic evidence, and clinical evidence, the latter reported following a hierarchy of evidence (that is, meta-analyses, clinical trials, observational studies, case series)
The STEP 8 trial directly compared these two drugs and found that semaglutide achieved 15.8% weight loss compared with 6.4% for liraglutide over 68 weeks
We can offer you products of the highest caliber at the most competitive rates